Court finds infringement after 2 day bench trial
In Re: Alfuzosin Hydrochloride Patent Litigation, MDL Docket No. 08-md-1941a-GMS, May 14, 2010.
Sleet, C. J. The court finds that the plaintiffs have proven by the preponderance of the evidence that the defendant Mylan’s proposed 10 mg extended release alfuzosin hydrochloride tablets will infringe the asserted claims of the '491 patent. The court further finds that Mylan will induce infringement of the asserted claims of the '491 patent.
The Court finds that the manufacture, use, or sale of Mylan's proposed generic alfuzosin hydrochloride product would infringe and will induce infringement of the asserted claims of the '491 patent.
